Nothing Special   »   [go: up one dir, main page]

BR112012032206A2 - comparações de amostras de proteínas - Google Patents

comparações de amostras de proteínas

Info

Publication number
BR112012032206A2
BR112012032206A2 BR112012032206A BR112012032206A BR112012032206A2 BR 112012032206 A2 BR112012032206 A2 BR 112012032206A2 BR 112012032206 A BR112012032206 A BR 112012032206A BR 112012032206 A BR112012032206 A BR 112012032206A BR 112012032206 A2 BR112012032206 A2 BR 112012032206A2
Authority
BR
Brazil
Prior art keywords
protein
sample
sitrs
digestion
comparisons
Prior art date
Application number
BR112012032206A
Other languages
English (en)
Inventor
Anton V Manuilov
David H Lee
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of BR112012032206A2 publication Critical patent/BR112012032206A2/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

comparações de amostras de proteínas. são fornecidos métodos para detectar quantitativa e/ou quantitativamente a presença de mutações, modificações ou impurezas em uma amostra de proteína. os métodos utilizam variantes de aminoácidos isotopicamente marcadas incorporadoas nas proteínas antes da digestão de proteínas, de forma a permitir comparações de duas amostras de proteína em cromatografia líquida bottom-up. as medições obtidas pela presenta invenção levam em consideração não apenas as massas dos peptídeos gerados durante a digestão proteolítica, mas também a abundância de cada peptídeo resultante. a medição da abundância de peptídeos pela ms é permitida através da utilização de uma amostra sitrs que é misturada com uma proteína não-marcada antes da digestão das proteínas. tal como aqui utilizado, o termo "amostra sitrs" ou "padrão sitrs" significa uma proteína (por exemplo, um anticorpo) de sequência conhecida, etiquetada com uma variante estável marcada isotopicamente em pelo menos um aminoácido presente na proteína.
BR112012032206A 2010-06-16 2011-06-16 comparações de amostras de proteínas BR112012032206A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35526910P 2010-06-16 2010-06-16
PCT/US2011/040669 WO2011159878A1 (en) 2010-06-16 2011-06-16 Comparison of protein samples

Publications (1)

Publication Number Publication Date
BR112012032206A2 true BR112012032206A2 (pt) 2016-10-04

Family

ID=45329013

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012032206A BR112012032206A2 (pt) 2010-06-16 2011-06-16 comparações de amostras de proteínas

Country Status (15)

Country Link
US (1) US9170262B2 (pt)
EP (1) EP2582380A4 (pt)
JP (1) JP2013528818A (pt)
KR (1) KR20130088131A (pt)
CN (1) CN103025342A (pt)
AU (1) AU2011268310A1 (pt)
BR (1) BR112012032206A2 (pt)
CA (1) CA2802057A1 (pt)
MX (1) MX2012014838A (pt)
NZ (1) NZ604013A (pt)
RU (1) RU2013101779A (pt)
SG (1) SG186302A1 (pt)
TW (1) TW201207383A (pt)
WO (1) WO2011159878A1 (pt)
ZA (1) ZA201209390B (pt)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2295450B1 (en) 2000-09-29 2015-01-28 Merck Sharp & Dohme Corp. Pegylated interleukin-10
EP2468293B1 (en) 2006-09-28 2014-10-22 Merck Sharp & Dohme Corp. Use of pegylated il-10 to prevent metastasis of a cancer or tumor to the lung
TW201239355A (en) 2011-03-23 2012-10-01 Abbott Lab Methods and systems for the analysis of protein samples
WO2012164956A1 (ja) * 2011-06-01 2012-12-06 株式会社ツムラ パターン又はｆｐの特徴量作成方法、作成プログラム、及び作成装置
RU2679889C2 (ru) 2013-04-18 2019-02-14 Армо Байосайенсиз, Инк. Способы применения интерлейкина-10 для лечения заболеваний и расстройств
EP3434277A1 (en) * 2013-06-17 2019-01-30 Armo Biosciences, Inc. Method for assessing protein identity and stability
EP3038642A4 (en) 2013-08-30 2017-01-18 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
WO2015056187A1 (en) * 2013-10-18 2015-04-23 Dr. Reddy’S Laboratories Limited In-vitro method for determining fate of polypeptide variant
KR20160079114A (ko) 2013-11-11 2016-07-05 아르모 바이오사이언시스 인코포레이티드 질환 및 장애를 치료하기 위한 인터류킨-10을 사용하는 방법
CN106573072A (zh) 2014-06-02 2017-04-19 阿尔莫生物科技股份有限公司 降低血清胆固醇的方法
CN107001438A (zh) 2014-10-14 2017-08-01 阿尔莫生物科技股份有限公司 白细胞介素‑15组合物及其用途
CA2963995A1 (en) 2014-10-22 2016-04-28 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
WO2016126615A1 (en) 2015-02-03 2016-08-11 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
WO2016191587A1 (en) 2015-05-28 2016-12-01 Armo Biosciences, Inc. Pegylated interleukin-10 for use in treating cancer
MX2018002298A (es) 2015-08-25 2018-07-06 Armo Biosciences Inc Metodos de uso de interleucina 10 para el tratamiento de enfermedades y trastornos.
US11698378B2 (en) * 2015-09-25 2023-07-11 Children's Medical Center Corporation Methods and compositions for tauopathy diagnosis and treatment
US11802879B2 (en) 2016-03-02 2023-10-31 Waters Technologies Corporation Identification and quantification of conjugated peptides in antibody drug conjugates by mass spectrometry
JP6943872B2 (ja) * 2016-03-25 2021-10-06 ジェネンテック， インコーポレイテッド 多重全抗体及び抗体複合体化薬物定量化アッセイ
CN105785048B (zh) * 2016-04-15 2017-07-28 同济大学 基于轻同位素近同重标记的整体蛋白质定量分析方法
CN105866429B (zh) * 2016-05-06 2017-12-15 同济大学 基于自带电荷同位素试剂的生物分子标记和定量分析方法
US11385238B2 (en) * 2017-06-30 2022-07-12 Amgen Inc. Methods of protein clips recovery
WO2019094752A1 (en) * 2017-11-09 2019-05-16 University Of Washington A mistranslation method for assessing the effects of amino acid substitutions on protein stability and function
CN109856253A (zh) * 2017-11-30 2019-06-07 江苏众红生物工程创药研究院有限公司 一种peg修饰蛋白多关键参数同时检测方法
TWI786265B (zh) * 2018-02-02 2022-12-11 美商再生元醫藥公司 用於表徵蛋白質二聚合之系統及方法
US11335547B2 (en) * 2018-04-10 2022-05-17 Dh Technologies Development Pte. Ltd. Top down analysis of antibodies in mass spectrometry
EP3833775A1 (en) 2018-08-08 2021-06-16 Regeneron Pharmaceuticals, Inc. Use of lc-ms/ms to quantitate protein biomarkers
EP3980787A4 (en) * 2019-06-06 2023-06-14 Dr. Reddy's Laboratories Ltd. PROCEDURE FOR IDENTIFICATION AND ABSOLUTE QUANTIFICATION OF PRODUCT-RELATED IMPURITIES IN A PROTEIN USING HIGH RESOLUTION MASS SPECTROMETRY

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
US5476996A (en) 1988-06-14 1995-12-19 Lidak Pharmaceuticals Human immune system in non-human animal
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
WO1990003430A1 (en) 1988-09-23 1990-04-05 Cetus Corporation Cell culture medium for enhanced cell growth, culture longevity and product expression
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
DK0585287T3 (da) 1990-07-10 2000-04-17 Cambridge Antibody Tech Fremgangsmåde til fremstilling af specifikke bindingsparelementer
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
AU1545692A (en) 1991-03-01 1992-10-06 Protein Engineering Corporation Process for the development of binding mini-proteins
ATE269401T1 (de) 1991-04-10 2004-07-15 Scripps Research Inst Bibliotheken heterodimerer rezeptoren mittels phagemiden
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
US20060141632A1 (en) * 2000-07-25 2006-06-29 The Procter & Gamble Co. New methods and kits for sequencing polypeptides
EP1430436A2 (en) 2000-10-19 2004-06-23 Target Discovery, Inc. Methods for determining protein and peptide terminal sequences
EP1420254A3 (en) * 2002-11-06 2004-05-26 F. Hoffmann-La Roche Ag Amyloid quantification
EP1628618A4 (en) * 2002-12-26 2009-09-09 Mountain View Pharmaceuticals POLYMER CONJUGATES OF CYTOKINES, CHEMOKINS, GROWTH FACTORS, POLYPEPTIDE HORMONES AND ANTAGONISTS THEREOF WITH PRESERVED RECEPTOR BINDING ACTIVITY
US7422865B2 (en) 2003-01-13 2008-09-09 Agilent Technologies, Inc. Method of identifying peptides in a proteomic sample
US7759130B2 (en) 2003-11-21 2010-07-20 Eisai R & D Management Co., Ltd. Mass spectrometric quantitation method for biomolecules based on metabolically labeled internal standards
US7811828B2 (en) * 2004-01-28 2010-10-12 Immatics Biotechnologies Gmbh Method for identifying and quantifying of tumuor-associated
JP2005300430A (ja) * 2004-04-14 2005-10-27 Shimadzu Corp ラベル化ペプチドの特異的検出法、および片在ピークの特異的検出法
EP2306198A1 (en) 2004-07-02 2011-04-06 Eisai R&D Management Co., Ltd. Method of analyzing protein structural affinity relationship
WO2006096704A2 (en) 2005-03-07 2006-09-14 Invitrogen Corporation Isotopically-labeled proteome standards
JP2006300758A (ja) * 2005-04-21 2006-11-02 Apro Life Science Institute Inc 内部標準ペプチドを用いて生体由来試料に含まれる標的タンパク質を定量する方法
CA2575507A1 (en) * 2006-05-25 2007-11-25 Her Majesty The Queen In Right Of Canada As Represented By The Minister Of The Department Of Fisheries And Oceans Quantification of vitellogenin
FI119190B (fi) * 2006-06-21 2008-08-29 Ipsat Therapies Oy Modifioitu beta-laktamaasi ja menetelmä sen valmistamiseksi
US8679771B2 (en) 2007-01-25 2014-03-25 The Regents Of The University Of California Specific N-terminal labeling of peptides and proteins in complex mixtures
US7943330B2 (en) * 2007-03-23 2011-05-17 Academia Sinica Tailored glycoproteomic methods for the sequencing, mapping and identification of cellular glycoproteins
GB0815576D0 (en) * 2008-08-28 2008-10-01 Lucas & Co Analysis of glycated proteins
GB2471155B (en) * 2009-05-06 2016-04-20 Agilent Technologies Inc Data dependent acquisition system for mass spectrometery and methods of use
EP2309262A1 (en) * 2009-10-06 2011-04-13 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Method for quantifying biomolecules
US8847152B2 (en) * 2009-11-30 2014-09-30 Physikron Sa Multiplexed tandem mass spectrometry method
TW201239355A (en) 2011-03-23 2012-10-01 Abbott Lab Methods and systems for the analysis of protein samples

Also Published As

Publication number Publication date
NZ604013A (en) 2014-10-31
JP2013528818A (ja) 2013-07-11
EP2582380A4 (en) 2014-03-05
US20110312010A1 (en) 2011-12-22
TW201207383A (en) 2012-02-16
RU2013101779A (ru) 2014-07-27
US9170262B2 (en) 2015-10-27
WO2011159878A1 (en) 2011-12-22
EP2582380A1 (en) 2013-04-24
AU2011268310A1 (en) 2013-01-10
KR20130088131A (ko) 2013-08-07
SG186302A1 (en) 2013-02-28
MX2012014838A (es) 2013-02-07
ZA201209390B (en) 2014-02-26
CN103025342A (zh) 2013-04-03
CA2802057A1 (en) 2011-12-22

Similar Documents

Publication Publication Date Title
BR112012032206A2 (pt) comparações de amostras de proteínas
BR112017018821A2 (pt) métodos para quantificação de níveis de insulina através de espectrometria de massa
BR112014026613A2 (pt) método para determinação quantitativa de impureza presente em composição de produto de peptídeo, kit de reagentes para determinação da quantidade de impurezas em composição de produto lixisenatide e método para controle de qualidade de composição compreendendo um produto de peptídeo de exendina
BR112013023540A2 (pt) anticorpo, kit e método para a determinação de peptídeos amilóides
BR112017004899A2 (pt) detecção de proteínas mal dobradas
BR112016013138A2 (pt) mistura de peptídeos
EA201792045A1 (ru) Новый комплекс, содержащий проникающий в клетку пептид, карго-молекулу и пептидный агонист tlr
BR112014017645A2 (pt) molécula imunológica; polinucleotídeo; vetor; célula recombinante que compreende o vetor; método para produzir molécula imunológica; anticorpo ou fragmento de ligação de antígeno do mesmo; composição farmacêutica; uso da molécula imunológica, do anticorpo, do fragmento de ligação de anticorpo ou da composição farmacêutica; método diagnóstico para diagnosticar uma doença em um indivíduo, em que a doença é selecionada do grupo que consiste em câncer, uma doença autoimune ou uma doença infecciosa; ensaio para diagnosticar uma doença em uma amostra de tecido tomada de um indivíduo; uso de um anticorpo ou um fragmento que se liga especificamente à seq id no: 10; e método diagnóstico para determinar se realiza o uso ou administra a composição
AR092818A1 (es) Anticuerpo tau humanizado
BR112015008036A2 (pt) população de peptídeos isolados, método para detectar em uma amostra um anticorpo, método para diagnosticar erliquiose monocítica e/ou granulocítica e kit
BR112018071686A2 (pt) exibição de proteínas integrais de membrana em vírions extracelulares envelopados de poxvírus
BR112015005887A2 (pt) quantificação de tiroglobulina por espectroscopia de massa
BR112017006598A2 (pt) anticorpo de repetições antidipeptídeo derivado de ser humano (dprs)
BR112014011563A2 (pt) métodos para detectar o papiloma-vírus humano e fornecer o prognóstico para carci-noma de células escamosas de cabeça e pescoço
MX2018009339A (es) Métodos para la identificación y análisis de secuencias de aminoácidos de las proteínas.
BR112019000098A2 (pt) proteína de fornecimento ao cérebro, método de tratamento e/ou profilaxia de distúrbios cerebrais em mamíferos que possuem ou encontram-se em risco de desenvolver o mencionado distúrbio e método de diagnóstico e/ou detecção de distúrbios cerebrais em mamíferos suspeitos de possuir ou que se encontram em risco de desenvolver o mencionado distúrbio
BR112013032088A2 (pt) "polipeptídeo, composição farmacêutica e seu uso"
MX2022010954A (es) Dispositivo para la deteccion de proteinas mal plegadas y metodos de uso del mismo.
WO2011109112A3 (en) Method of detecting tau protein and tau fragments in serum
BR112019009565A2 (pt) método de avaliação da cinética molecular e método de rastreamento
Lewis et al. Mass spectrometric identification of dystrophin isoform Dp427 by on-membrane digestion of sarcolemma from skeletal muscle
WO2014117680A3 (zh) 外周血细胞TRPC6mRNA水平用于早期预测/诊断老年性痴呆
GB2522131A (en) Isotopic labelling of proteins
BR112017020606A2 (pt) ?composições e métodos de uso de peptídeos de interleucina-10 e anticorpos anti-interleucina?
Popov et al. Mass spectrometric identification of posttranslational modifications in transthyretin from human blood

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]